Development of Sulfasalazine Resistance in Human T Cells Induces Expression of the Multidrug Resistance Transporter ABCG2 (BCRP) and Augmented Production of TNFalpha

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2004 Jan 15

PMID 14722201

Citations 21

Authors

J van der Heijden

M C de Jong

B A C Dijkmans

W F Lems

R Oerlemans

I Kathmann

C G Schalkwijk

G L Scheffer

R J Scheper

G Jansen

Affiliations

Soon will be listed here.

Abstract

Objective: To determine whether overexpression of cell membrane associated drug efflux pumps belonging to the family of ATP binding cassette (ABC) proteins contributes to a diminished efficacy of sulfasalazine (SSZ) after prolonged cellular exposure to this disease modifying antirheumatic drug (DMARD).

Methods: A model system of human T cells (CEM) was used to expose cells in vitro to increasing concentrations of SSZ for a period of six months. Cells were then characterised for the expression of drug efflux pumps: P-glycoprotein (Pgp, ABCB1), multidrug resistance protein 1 (MRP1, ABCC1), and breast cancer resistance protein (BCRP, ABCG2).

Results: Prolonged exposure of CEM cells to SSZ provoked resistance to SSZ as manifested by a 6.4-fold diminished antiproliferative effect of SSZ compared with parental CEM cells. CEM cells resistant to SSZ (CEM/SSZ) showed a marked induction of ABCG2/BCRP, Pgp expression was not detectable, while MRP1 expression was even down regulated. A functional role of ABCG2 in SSZ resistance was demonstrated by 60% reversal of SSZ resistance by the ABCG2 blocker Ko143. Release of the proinflammatory cytokine tumour necrosis factor alpha (TNFalpha) was threefold higher in CEM/SSZ cells than in CEM cells. Moreover, twofold higher concentrations of SSZ were required to inhibit TNFalpha release from CEM/SSZ cells compared with CEM cells.

Conclusion: Collectively, ABCG2 induction, augmented TNFalpha release, and less efficient inhibition of TNFalpha production by SSZ may contribute to diminished efficacy after prolonged exposure to SSZ. These results warrant further clinical studies to verify whether drug efflux pumps, originally identified for their roles in cytostatic drug resistance, can also be induced by SSZ or other DMARDs.

Citing Articles

ATP-Binding Cassette Subfamily G Member 2 in Acute Myeloid Leukemia: A New Molecular Target?.

Damiani D, Tiribelli M Biomedicines. 2024; 12(1).

PMID: 38255216 PMC: 10813371. DOI: 10.3390/biomedicines12010111.

Toward Overcoming Treatment Failure in Rheumatoid Arthritis.

Wang Z, Huang J, Xie D, He D, Lu A, Liang C Front Immunol. 2022; 12:755844.

PMID: 35003068 PMC: 8732378. DOI: 10.3389/fimmu.2021.755844.

Beta1 integrin blockade overcomes doxorubicin resistance in human T-cell acute lymphoblastic leukemia.

Berrazouane S, Boisvert M, Salti S, Mourad W, Al-Daccak R, Barabe F Cell Death Dis. 2019; 10(5):357.

PMID: 31043590 PMC: 6494825. DOI: 10.1038/s41419-019-1593-2.

Rheumatoid Arthritis Disease Activity Is Determinant for ABCB1 and ABCG2 Drug-Efflux Transporters Function.

Atisha-Fregoso Y, Lima G, Pascual-Ramos V, Banos-Pelaez M, Fragoso-Loyo H, Jakez-Ocampo J PLoS One. 2016; 11(7):e0159556.

PMID: 27442114 PMC: 4956301. DOI: 10.1371/journal.pone.0159556.

Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.

Andersen V, Svenningsen K, Knudsen L, Hansen A, Holmskov U, Stensballe A World J Gastroenterol. 2015; 21(41):11862-76.

PMID: 26557010 PMC: 4631984. DOI: 10.3748/wjg.v21.i41.11862.

References

Dean M, Allikmets R . Complete characterization of the human ABC gene family. J Bioenerg Biomembr. 2002; 33(6):475-9. DOI: 10.1023/a:1012823120935. View

Landewe R, Boers M, Verhoeven A, Westhovens R, van de Laar M, Markusse H . COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002; 46(2):347-56. DOI: 10.1002/art.10083. View

Ross D, Yang W, Abruzzo L, Dalton W, Schneider E, Lage H . Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst. 1999; 91(5):429-33. DOI: 10.1093/jnci/91.5.429. View

Ambudkar S, Dey S, Hrycyna C, Ramachandra M, Pastan I, Gottesman M . Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999; 39:361-98. DOI: 10.1146/annurev.pharmtox.39.1.361. View

Hooijberg J, Broxterman H, Kool M, Assaraf Y, Peters G, Noordhuis P . Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999; 59(11):2532-5. View

Tsai S, Liang Y, Lin-Shiau S, Lin J . Suppression of TNFalpha-mediated NFkappaB activity by myricetin and other flavonoids through downregulating the activity of IKK in ECV304 cells. J Cell Biochem. 1999; 74(4):606-15. View

FOLEY G, Lazarus H, Farber S, Uzman B, Boone B, McCarthy R . CONTINUOUS CULTURE OF HUMAN LYMPHOBLASTS FROM PERIPHERAL BLOOD OF A CHILD WITH ACUTE LEUKEMIA. Cancer. 1965; 18:522-9. DOI: 10.1002/1097-0142(196504)18:4<522::aid-cncr2820180418>3.0.co;2-j. View

Klein I, Sarkadi B, Varadi A . An inventory of the human ABC proteins. Biochim Biophys Acta. 1999; 1461(2):237-62. DOI: 10.1016/s0005-2736(99)00161-3. View

Liptay S, Bachem M, Hacker G, Adler G, Debatin K, Schmid R . Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine. Br J Pharmacol. 1999; 128(7):1361-9. PMC: 1571782. DOI: 10.1038/sj.bjp.0702937. View

10.

De Bruin M, Miyake K, Litman T, Robey R, Bates S . Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett. 2000; 146(2):117-26. DOI: 10.1016/s0304-3835(99)00182-2. View

11.

Huang T, Wuerzberger-Davis S, Seufzer B, Shumway S, Kurama T, Boothman D . NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. J Biol Chem. 2000; 275(13):9501-9. DOI: 10.1074/jbc.275.13.9501. View

12.

Scheffer G, Maliepaard M, Pijnenborg A, van Gastelen M, de Jong M, Schroeijers A . Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res. 2000; 60(10):2589-93. View

13.

Gottesman M, Fojo T, Bates S . Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1):48-58. DOI: 10.1038/nrc706. View

14.

van der Kolk D, Vellenga E, Scheffer G, Muller M, Bates S, Scheper R . Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood. 2002; 99(10):3763-70. DOI: 10.1182/blood.v99.10.3763. View

15.

Borst P, Elferink R . Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002; 71:537-92. DOI: 10.1146/annurev.biochem.71.102301.093055. View

16.

ODell J, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff P . Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002; 46(5):1164-70. DOI: 10.1002/art.10228. View

17.

Jonker J, Buitelaar M, Wagenaar E, van der Valk M, Scheffer G, Scheper R . The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A. 2002; 99(24):15649-54. PMC: 137771. DOI: 10.1073/pnas.202607599. View

18.

Allen J, van Loevezijn A, Lakhai J, van der Valk M, van Tellingen O, Reid G . Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther. 2002; 1(6):417-25. View

19.

Allen J, Schinkel A . Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther. 2002; 1(6):427-34. View

20.

van der Heijden J, de Jong M, Dijkmans B, Lems W, Oerlemans R, Kathmann I . Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs. Ann Rheum Dis. 2004; 63(2):131-7. PMC: 1754886. DOI: 10.1136/ard.2003.006494. View